Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Given Imaging predicts 2006 launch for third-generation PillCam SB:

This article was originally published in Clinica

Executive Summary

Given Imaging is developing a third-generation version of its ingestable video capsule, PillCam SB, for imaging the small bowel. The modified device, which is being developed in collaboration with Boise, Idaho-based Micron Technology and Ottawa, Canada firm Zarlink Semiconductor, is expected to become commercially available in 2006. It features an improved frame rate of four frames per second - the previous model's rate was two frames per second - and an increased operational time of nine hours - up from eight hours. PillCam SB is used for the direct visualisation of the small intestine and is approved for sale in more than 50 countries worldwide. Yoqneam, Israel-based Given said it is also conducting clinical trials of its PillCam COLON device.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel